MedTech & Diagnostics
NovoCure Executive Compensation (FY25)
NVCR · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 5, 2026
284 figures on this page: 282 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Total compensation for Frank Leonard, Chief Executive Officer, came to $6,975,329 in fiscal 2025, and Leonard's total was 19.8% higher than the $5,823,930 reported for fiscal 2024. The disclosed chief executive pay ratio for fiscal 2025 is 84:1, against median employee compensation of $148,799. Shareholders supported the say-on-pay proposal with 91.0% of votes cast for or against in favor at the meeting held June 3, 2026 for fiscal 2025. Companies named in the disclosed peer group include 10x Genomics, Inc., Align Technology, Alnylam Pharmaceuticals, Inc., CRISPR Therapeutics AG and Exact Sciences Corporation, among others.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Frank Leonard: $5,823,930 → $6,975,329 (19.8% higher)
Say-on-pay support: 97.5% → 91.0% (6.5 points lower)
CEO pay ratio: 10.9:1 → 84:1
Frequently asked questions
Answers drawn from the data on this page.
Who is NovoCure's chief executive and what were they paid?
Total compensation for Frank Leonard, Chief Executive Officer, came to $6,975,329 in fiscal 2025. Leonard's total was 19.8% higher than the $5,823,930 reported for fiscal 2024.
What was NovoCure's say-on-pay result?
Shareholders supported the say-on-pay proposal with 91.0% of votes cast for or against in favor at the meeting held June 3, 2026 for fiscal 2025.
Which companies are in NovoCure's peer group?
Companies named in the disclosed peer group include 10x Genomics, Inc., Align Technology, Alnylam Pharmaceuticals, Inc., CRISPR Therapeutics AG and Exact Sciences Corporation, among others.
What is NovoCure's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 84:1, against median employee compensation of $148,799.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Ashley Cordova Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Frank Leonard Executive Vice President, President Novocure US | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Ashley Cordova Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Frank Leonard Executive Vice President, President Novocure US | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Uri Weinberg Chief Medical and Innovation Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Ashley Cordova Former Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Frank Leonard Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Christoph Brackmann Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Uri Weinberg Chief Medical and Innovation Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Nicolas Leupin Former Chief Medical Officer Departed during or after this year | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Michael Puri Chief Human Resources Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Ashley Cordova | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Ashley Cordova | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Ashley Cordova | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Christoph Brackmann | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Christoph Brackmann | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Christoph Brackmann | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Frank Leonard | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Frank Leonard | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Frank Leonard | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Frank Leonard | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael Puri | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Michael Puri | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Michael Puri | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Nicolas Leupin | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Nicolas Leupin | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
| Nicolas Leupin | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Uri Weinberg | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Uri Weinberg | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Uri Weinberg | PSU | ◇ | ◇ | ◇ | — | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Uri Weinberg | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2033 | |
| Option | ◇ | — | ◇ | 2/29/2032 | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/26/2034 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| Frank Leonard | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/29/2032 | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/26/2034 | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 10/31/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/27/2033 | |
| PSU | ◇ | ◇ | — | — | |
| Ashley Cordova | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/26/2034 | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| Option | ◇ | — | ◇ | 2/27/2033 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 2/29/2032 | |
| PSU | ◇ | ◇ | — | — | |
| Michael Puri | RSU | ◇ | ◇ | — | — |
| PSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| Nicolas Leupin | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/3/2035 | |
| Christoph Brackmann | Option | ◇ | — | ◇ | 11/3/2034 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/3/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Asaf Danziger | — | — | — | — | — | — | ◇ |
William Doyle Board chair | — | — | — | — | — | — | ◇ |
William Vernon Lead independent director | ◇ | ◇ | ◇ | — | — | — | ◇ |
Martin Madden | ◇ | — | ◇ | — | — | — | ◇ |
Jeryl Hilleman | ◇ | ◇ | ◇ | — | — | — | ◇ |
Timothy Scannell | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kinyip Gabriel Leung | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kristin Stafford | ◇ | ◇ | ◇ | — | — | — | ◇ |
David Hung | ◇ | ◇ | ◇ | — | — | — | ◇ |
Allyson Ocean | ◇ | ◇ | ◇ | — | — | — | ◇ |
Frank Leonard and Ashley Cordova served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 10x Genomics, Inc. TXG
- Align Technology ALGN
- Alnylam Pharmaceuticals, Inc. ALNY
- CRISPR Therapeutics AG CRSP
- Exact Sciences Corporation EXAS
- Exelixis, Inc EXEL
- Incyte Corporation INCY
- Inspire Medical Systems, Inc. INSP
- Insulet Corporation PODD
- iRhythm Technologies IRTC
- Teladoc Health, Inc. TDOC
- Zai Lab Limited ZLAB
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 3, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 4, 2025 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact NovoCure disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where NovoCure sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
284 figures on this page: 282 cited to the filing that reported them, 2 calculated from figures it prints.
282 cited to the filing
2 calculated from the filing
Documents cited
- 0001645113-26-000050Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001645113-26-0000332025 DIRECTOR COMPENSATION · 2025 Director Compensation Table · 2025 Grants of Plan-Based Awards · 2025 Summary Compensation Table · and 1 more section
- 0001645113-25-000011Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001645113-25-0000052024 Summary Compensation Table
- 0001645113-24-0000112023 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “NovoCure executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/NVCR (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about NovoCure and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers NovoCure discloses
The companies named in NVCR's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}